Dashboard
Manage Tickers

XLO Xilio Therapeutics, Inc.

Nasdaq xiliotx.com


$ 0.74 $ -0.03 (-3.76 %)    

Monday, 10-Nov-2025 19:35:02 EST
CLICK TO SEE RELEVANT LITIGATION UPDATES
QQQ $ 623.82 $ 4.38 (0.71 %)
DIA $ 473.95 $ 1.94 (0.41 %)
SPY $ 681.69 $ 4.15 (0.61 %)
TLT $ 89.46 $ 0.06 (0.07 %)
GLD $ 380.15 $ 2.40 (0.64 %)
$ 0.8048
$ 0.83
$ 0.73 x 500
$ 0.85 x 300
$ 0.76 - $ 0.84
$ 0.62 - $ 1.70
1,339,889
na
41.71M
$ 1.09
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-14-2025 06-30-2025 10-Q
2 05-08-2025 03-31-2025 10-Q
3 03-11-2025 12-31-2024 10-K
4 11-07-2024 09-30-2024 10-Q
5 08-08-2024 06-30-2024 10-Q
6 05-14-2024 03-31-2024 10-Q
7 04-01-2024 12-31-2023 10-K
8 11-09-2023 09-30-2023 10-Q
9 08-14-2023 06-30-2023 10-Q
10 05-09-2023 03-31-2023 10-Q
11 03-02-2023 12-31-2022 10-K
12 11-09-2022 09-30-2022 10-Q
13 08-09-2022 06-30-2022 10-Q
14 05-12-2022 03-31-2022 10-Q
15 03-01-2022 12-31-2021 10-K
16 12-02-2021 09-30-2021 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

Core News & Articles
12 Health Care Stocks Moving In Monday's A...
11/10/2025 21:07:39

xilio-therapeutics-announces-phase-2-data-for-vilastobart-in-combination-with-atezolizumab-continues-to-demonstrate-differentiated-and-generally-well-tolerated-safety-profile
Xilio Therapeutics Announces Phase 2 Data ...
11/07/2025 14:17:55

40% ORR in heavily pre-treated patients with MSS mCRC without liver metastases and with high plasma tumor mutational burden (TM...

xilio-therapeutics-presents-new-data-across-portfolio-including-preclinical-data-highlighting-potential-for-masked-t-cell-engager-platform-and-programs-as-well-as-phase-1-data-for-efarindodekin-alfa-and-phase-2-data-related-to-ctdna-for-vilastobart-at-sitc-2025
Xilio Therapeutics Presents New Data Acros...
11/07/2025 14:14:57

Preclinical data support best-in-class potential of masked T cell engager programs and platform utilizing Xilio's ATACR and...

xilio-therapeutics-announces-it-will-present-late-breaking-phase-2-data-for-vilastobart-at-the-sitc-40th-annual-meeting-nov-59-2025
Xilio Therapeutics Announces It Will Prese...
10/30/2025 13:05:45

Xilio Therapeutics, Inc. (NASDAQ:XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno...

xilio-therapeutics-hits-175m-milestone-in-gilead-partnership-shares-new-phase-1-data-on-efarindodekin-alfa
Xilio Therapeutics Hits $17.5M Milestone I...
09/09/2025 11:43:50

In addition, today Xilio announced the achievement of a $17.5 million development milestone under Xilio's license agreement...

xilio-therapeutics-initiates-patient-dosing-in-phase-2-of-an-ongoing-phase-12-clinical-trial-evaluating-efarindodekin-alfa-as-monotherapy-in-patients-with-certain-advanced-solid-tumors
Xilio Therapeutics Initiates Patient Dosin...
09/09/2025 11:37:32

Phase 1 data for efarindodekin alfa (XTX301) demonstrate promising anti-tumor activity in patients with advanced solid tumorsAc...

xilio-therapeutics-q2-eps-016-misses-008-estimate-sales-8084m-miss-8210m-estimate
Xilio Therapeutics Q2 EPS $(0.16) Misses $...
08/14/2025 11:33:52

Xilio Therapeutics (NASDAQ:XLO) reported quarterly losses of $(0.16) per share which missed the analyst consensus estimate of $...

Core News & Articles
12 Health Care Stocks Moving In Wednesday'...
06/18/2025 21:05:53

reported-earlier-xilio-therapeutics-closes-50m-public-offering-with-potential-to-raise-up-to-150m-through-warrant-exercises-by-2026
Reported Earlier, Xilio Therapeutics Close...
06/06/2025 06:44:14

Total gross proceeds of up to $150.0 million before the end of 2026 if all Series B warrants and Series C warrants are exercise...

Core News & Articles
12 Health Care Stocks Moving In Monday's I...
06/02/2025 17:06:00

nasdaq-edges-higher-ism-manufacturing-pmi-falls-in-may
Nasdaq Edges Higher; ISM Manufacturing PMI...
06/02/2025 16:49:43

dow-dips-over-300-points-campbells-posts-upbeat-earnings
Dow Dips Over 300 Points; Campbell's Posts...
06/02/2025 14:16:13

xilio-therapeutics-prices-50m-public-offering-of-pre-funded-warrants-and-series-a-b-c-warrants-to-purchase-667m-shares-each-at-07499-per-unit-co-may-receive-additional-gross-proceeds-from-the-offering-of-up-to-100m-before-deducting-underwriting-discounts-and-commissions-and-offering-expenses
Xilio Therapeutics Prices $50M Public Offe...
06/02/2025 12:48:57

Xilio Therapeutics, Inc. (NASDAQ:XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno...

Core News & Articles
12 Health Care Stocks Moving In Monday's P...
06/02/2025 12:07:43

why-blueprint-medicines-shares-are-trading-higher-by-27-here-are-20-stocks-moving-premarket
Why Blueprint Medicines Shares Are Trading...
06/02/2025 11:29:14

xilio-therapeutics-commenced-an-underwritten-public-offering-of-pre-funded-warrants-to-purchase-shares-terms-not-disclosed
Xilio Therapeutics Commenced An Underwritt...
06/02/2025 10:13:36

reported-saturday-xilios-tumor-activated-anti-ctla-4-vilastobart-shows-26-objective-response-rate-with-durable-responses-and-low-colitis-in-mss-crc-without-liver-metastases
Reported Saturday, Xilio's Tumor-Activated...
06/02/2025 08:53:46

26% preliminary objective response rate observed in heavily pre-treated patients with metastatic microsatellite stable colorect...

Core News & Articles
12 Health Care Stocks Moving In Tuesday's ...
05/13/2025 21:06:18

Core News & Articles
12 Health Care Stocks Moving In Tuesday's ...
05/13/2025 17:06:46

Core News & Articles
12 Health Care Stocks Moving In Tuesday's ...
05/13/2025 12:10:18

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION